Piper Sandler initiated coverage of Inventiva (IVA) with an Overweight rating and $26 price target The company is developing its lead asset, lanifibranor, in metabolic dysfunction-associated steatohepatitis with a Phase 3 readout in the second half of 2026, the analyst tells investors in a research note. The firm sees a buying opportunity at current share levels, saying Inventiva has an oral asset that is “de-risked” for probability of success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating
- Inventiva’s Strong Financial Position and Promising Phase 3 Trial Drive Buy Rating
- Inventiva Announces Preliminary First-Half 2025 Financial Results
- Inventiva Announces Leadership Changes to Drive Growth
- Inventiva CMO Michael Cooreman to depart, Jason Campagna to succeed